VYNE Therapeutics Inc.

VYNE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$7,280-$5,755-$8,611-$12,022
Dep. & Amort.$6$6$6$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$487$529$763$699
Change in WC-$159-$5,369-$3,295$2,865
Other Non-Cash-$150-$214-$324-$541
Operating Cash Flow-$7,096-$10,803-$11,461-$8,999
Investing Activities
PP&E Inv.$0$0$0-$117
Net Acquisitions$0$0$0$0
Inv. Purchases-$6,798-$9,575-$13,769-$10,045
Inv. Sales/Matur.$11,200$14,250$33,600$22,900
Other Inv. Act.$0$0$0$0
Investing Cash Flow$4,402$4,675$19,831$12,738
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0-$34$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$7$0-$87-$132
Financing Cash Flow-$7-$34-$87-$132
Forex Effect$0$0$0$0
Net Chg. in Cash-$2,701-$6,162$8,283$3,607
Supplemental Information
Beg. Cash$22,047$28,209$19,926$16,319
End Cash$19,346$22,047$28,209$19,926
Free Cash Flow-$7,096-$10,803-$11,461-$9,116